E
Elizabeth A. Magnuson
Researcher at University of Missouri–Kansas City
Publications - 76
Citations - 5971
Elizabeth A. Magnuson is an academic researcher from University of Missouri–Kansas City. The author has contributed to research in topics: Cost effectiveness & Valve replacement. The author has an hindex of 31, co-authored 70 publications receiving 5106 citations. Previous affiliations of Elizabeth A. Magnuson include Mayo Clinic & New York University.
Papers
More filters
Journal ArticleDOI
Strategies for Multivessel Revascularization in Patients with Diabetes
Michael E. Farkouh,Michael J. Domanski,Lynn A. Sleeper,Flora S. Siami,George Dangas,Michael J. Mack,David J. Cohen,Yves Rosenberg,Scott D. Solomon,Akshay S. Desai,Bernard J. Gersh,Elizabeth A. Magnuson,Alexandra J. Lansky,Robin Boineau,Jesse Weinberger,Krishnan Ramanathan,J. Eduardo Sousa,Jamie Rankin,Balram Bhargava,John B. Buse,Whady Hueb,Craig R. Smith,Victoria Muratov,Sameer Bansilal,Spencer B. King,Michel E. Bertrand,Valentin Fuster +26 more
TL;DR: For patients with diabetes and advanced coronary artery disease, CABG was superior to PCI in that it significantly reduced rates of death and myocardial infarction, with a higher rate of stroke.
Journal ArticleDOI
Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis
Suresh Vedantham,Samuel Z. Goldhaber,Jim A. Julian,Susan R. Kahn,Michael R. Jaff,David J. Cohen,Elizabeth A. Magnuson,Mahmood K. Razavi,Anthony J. Comerota,Heather L. Gornik,Timothy P. Murphy,Lawrence M. Lewis,James R. Duncan,Patricia Nieters,Mary Clare Derfler,Marc L. Filion,Chu Shu Gu,Stephen T. Kee,Joseph R. Schneider,Nael Saad,Morey A. Blinder,Stephan Moll,David Sacks,Judith C. Lin,John H. Rundback,Mark J. Garcia,Rahul Razdan,Eric VanderWoude,Vasco Marques,Clive Kearon +29 more
TL;DR: Among patients with acute proximal deep‐vein thrombosis, the addition of pharmacomechanical catheter‐directed thrombolysis to anticoagulation did not result in a lower risk of the post‐thrombotic syndrome but did result in an higher risk of major bleeding.
Journal ArticleDOI
Health-Related Quality of Life After Transcatheter Aortic Valve Replacement in Inoperable Patients With Severe Aortic Stenosis
Matthew R. Reynolds,Elizabeth A. Magnuson,Yang Lei,Martin B. Leon,Craig R. Smith,Lars G. Svensson,John G. Webb,Vasilis Babaliaros,Bruce Bowers,William F. Fearon,Howard C. Herrmann,Samir Kapadia,Susheel Kodali,Raj Makkar,Augusto Pichard,David J. Cohen +15 more
TL;DR: Among inoperable patients with severe aortic stenosis, compared with standard care, TAVR resulted in significant improvements in health-related quality of life that were maintained for at least 1 year.
Journal ArticleDOI
Health-Related Quality of Life After Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis: Results From the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A)
Matthew R. Reynolds,Elizabeth A. Magnuson,Kaijun Wang,Vinod H. Thourani,Mathew R. Williams,Alan Zajarias,Charanjit S. Rihal,David L. Brown,Craig R. Smith,Martin B. Leon,David J. Cohen +10 more
TL;DR: In high-risk patients with severe AS, health status improved substantially between baseline and 1 year after either TAVR or AVR.
Journal ArticleDOI
Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Standard Care Among Inoperable Patients With Severe Aortic Stenosis Results From the Placement of Aortic Transcatheter Valves (PARTNER) Trial (Cohort B)
Matthew R. Reynolds,Matthew R. Reynolds,Elizabeth A. Magnuson,Kaijun Wang,Yang Lei,Katherine Vilain,Joshua Walczak,Susheel Kodali,John M. Lasala,William W. O'Neill,Charles J. Davidson,Craig R. Smith,Martin B. Leon,David J. Cohen +13 more
TL;DR: The PARTNER trial as mentioned in this paper randomized patients with symptomatic, severe aortic stenosis who were not candidates for surgery to Transcatheter Aortic Valve Replacement (TAVR) or standard therapy.